SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Looking Into AbbVie's Recent Short Interest
Benzinga12:45 ET
Bausch + Lomb Sale Process Gains Momentum As TPG And Blackstone Join Forces
BenzingaOct 14 10:04 ET
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
wallstreetcnOct 14 09:14 ET
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
BenzingaOct 11 13:12 ET · Ratings
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Seeking AlphaOct 11 12:41 ET
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
BenzingaOct 11 12:00 ET

Comments

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

1

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

+1

CPI hits 3-year low: How will it sway the Fed rate decision?

15

3

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?

5

1

Meltyy

Aug 6 02:51

$XBI down 3% today and 5% since before last Friday’s jobs report.

$SPDR S&P Biotech ETF (XBI.US)$
» Is this a smid-cap biopharma buying opportunity? 🤔
Stock market sell-off, e.g., $NASDAQ, started late last week on weak jobs data
XBI/smid-cap biopharma were part of sell-off
But..
» Is this sell-off justified for smid-cap biopharma?
» Is this a buying opportunity for smid-cap biopharma?
💡 Lower economic/jobs data = more likely entering lowering interest rate cycle for Fed Reserve
Usually go...

1

Goodjobguys

Aug 1 09:43

7 Cheap But Risky Biotech Stocks? Funds moving from big corporations to Small Caps?

$Immuneering (IMRX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$ $S&P 500 Index (.SPX.US)$ $BioAtla (BCAB.US)$ $Gilead Sciences (GILD.US)$ $Affimed NV (AFMD.US)$ $Instil Bio (TIL.US)$ $Nkarta (NKTX.US)$
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...

10

1

XBI SPDR S&P Biotech ETF

Trade Overview

Capital Trend

News

Comments